Drug-conjugated monoclonal antibodies in advanced/metastatic breast cancer

• Autores: Aldecoa-Bedoya, Franklin, Falcón, Silvia
• Formato: artículo
• Fecha de Publicación: 2023
• Institución: Fundación Instituto Hipólito Unanue
• Repositorio: Diagnóstico
• Lenguaje: español
• OAI Identifier: oai:revistadiagnostico.fihu.org.pe:article/427
• Enlace del recurso: https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/427
• Nivel de acceso: acceso abierto
• Materia: Anticuerpos monoclonales; inmunoconjugados; cáncer de mama; citostáticos; Antibody drug conjugates; antibodies; monoclonal; breast cancer; cytostatic agents

The goal of this report is to analyze, in a general way, the structure and mechanism of action of drug-conjugated monoclonal (ADC) and examine the studies that led their approval in advanced/metastatic breast cancer (ABC). PubMed, Scopus and SciELO databases were used between 2000 and 2022; Bibliographic references were searched for the keywords associated with ADC and ABC. ADCs combine classical monoclonal assays with a linker and a cytotoxic payload to destroy cancer cells in a targeted manner, when there is internalization of the corresponding receptor. There are currently three ACDs that have been approved for the treatment of CMAM; studies that have demonstrated significant advantages in progression-free survival when compared to standard treatment; evaluation of its main adverse events; implications for its management in our everyday lives; and potential inclusion in the current treatment of CMAM.